GlassScriptPhysician profile
Nasima Begum
NPI 1578547519
$5,769.88
in general payments reported to CMS, 2019-2025
22 companies · $883 in 2025
The $883 reported for 2025 was more than what 77% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $762 · 2020: $595 · 2021: $793 · 2022: $787 · 2023: $1,030 · 2024: $920 · 2025: $883.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,739 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,738.63 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,137.34 | 2019-2025 | Dovato, Cabenuva, Apretude |
| Gilead Sciences, INC. | $915.05 | 2019-2025 | Veklury |
| Abbvie INC. | $670.16 | 2021-2025 | Avycaz, Dalvance, Teflaro |
| Merck Sharp & Dohme LLC | $636.01 | 2019-2025 | Recarbrio, Zerbaxa, Dificid |
| Insmed, INC. | $620.72 | 2019-2025 | Arikayce, Brinsupri |
| Cumberland Pharmaceuticals, INC. | $355.15 | 2021-2023 | Vibativ |
| Shionogi INC | $351.56 | 2022-2025 | Fetroja |
| Allergan, INC. | $308.47 | 2019-2020 | |
| Melinta Therapeutics, LLC | $178.22 | 2019-2024 | Rezzayo, Kimyrsa, Vabomere |
| Astellas Pharma US INC | $112.72 | 2021-2024 | Cresemba |
| Aimmune Therapeutics, INC. | $93.71 | 2023-2025 | Vowst |
| Theratechnologies INC. | $73.99 | 2021-2023 | Trogarzo, Egrifta |
| Baxter Healthcare | $69.98 | 2025 | Hillrom - Monarch Airway Clearance System, Hillrom - Volara System |
| Paratek Pharmaceuticals, INC. | $54.46 | 2023 | Nuzyra |
| Emd Serono, INC. | $43.84 | 2023 | Serostim |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $32.14 | 2019 | |
| Nabriva Therapeutics, Plc | $22.71 | 2020 | |
| La Jolla Pharmaceutical Company | $21.45 | 2025 | Zevtera |
| Tetraphase Pharmaceuticals, INC. | $21.37 | 2019 | |
| Pfizer INC. | $20.79 | 2023 | |
| Tactile Systems Technology INC | $16.54 | 2020 | |
| Mayne Pharma Commercial LLC | $13.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nasima Begum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.